Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms
Cette étude analyse l'association entre une utilisation de traitements antiangiogéniques et la survenue de dissection artérielle ou d'anévrisme chez des patients atteints d'un cancer
Anticancer drugs targeting angiogenesis act either directly on vascular endothelial growth factor (VEGF) receptors (VEGF inhibitors) or VEGF-mediated intracellular processes (tyrosine kinase inhibitors) or indirectly through downstream VEGF signaling within broader processes (mammalian target of rapamycin inhibitors and multiprotein kinase inhibitors). Although VEGF blockade may be implicated in arterial wall injuries, the literature on the association between antiangiogenic drugs and artery dissections or aneurysms is scant, comprising only a few case reports and 1 pharmacovigilance study conducted in Japan. The present study evaluated the association between all antiangiogenic drugs and dissections or aneurysms occurring in all arteries.
JAMA Oncology 2021